Nebenwirkungen · Simulect
Simulect 10 mg powder and solvent for solution for injection or infusion Simulect 10 mg powder for solution for injection or infusion · Abschnitt 4.8 · PDF-Seite 16
HOS-089036 · Präparat HOS-083755
Incidence of infectious episodes: The overall incidence and profile of viral, bacterial and fungal infections among patients treated with basiliximab or placebo in combination with dual and triple immunosuppressive therapy was comparable between the groups. The overall incidence of infections was 75.9% in the basiliximab group and 75.6% in the placebo group and the incidence of serious infections was 26.1% and 24.8%, respectively. The incidence of CMV infections was similar in both groups (14.6% vs. 17.3%), following either dual or triple therapy regimen (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-19T11:51:00Z · SHA-256 733fba3a740348b21107babe9d9387936dfd68357cde53822fb186eb4a9d7e0d · Passage 535ffcfb8c9b5cf03bb4af4a6b328d46cf08de86a21b540d0e0206ca64a2fe45 · Zeichen 2653–3232 im Abschnitt